

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) Combination of R-4-trimethylammonio-3-(tetradecyl-carbamoyl)-aminobutyrate or one of its pharmaceutically acceptable salts and met- formin or one of its pharmaceutically acceptable salts.

2. (Canceled).

3. (Currently Amended) Method for the treatment of type 2 diabetes comprising the administration ~~Use of the combination according to claim 1 for the preparation of a medicament for the treatment of type 2 diabetes.~~

4. (Currently Amended) ~~Use according to claim 3 for the preparation of a medicament with antidiabetic activity for the control of~~ Method for controlling glycaemia over the 24 hour period by administering the combination according to claim 1.

5. (Currently Amended) ~~Use~~ Method according to claim 4, ~~where~~ wherein ~~the medicament is useful for the control of glycaemia~~ is controlled far from mealtimes, and in the postabsorption and fasting conditions.

6. (Currently Amended) ~~Use~~ Method according to claim 2~~3~~ wherein said combination for the preparation of a medicament with antidiabetic activity, said medicament being devoid of the side effects typical of the individual components of said combination or having only substantially reduced side effects of that type.

7. (Currently Amended) ~~Use~~ Method according to claim 6, where said combination ~~medicament~~ is used for the treatment of diabetic patients for whom metformin is contraindicated or inadvisable.

8. (Currently Amended) ~~Use~~Method according to claim 6, where said ~~medicament combination~~ is indicated in patients suffering from one or more complications belonging to the group consisting of kidney damage, cardiac insufficiency, chronic liver damage, clinical proteinuria, peripheral vascular damage or lung damage.

9. (Original) Pharmaceutical composition containing the combination according to claim 1.

10. (Original) Pharmaceutical composition according to claim 9, containing subpharmacological doses of R-4-trimethyl-ammonio-3-(tetradecylcarbamoyl)-aminobutyrate or one of its pharmaceutically acceptable salts and of metformin or one of its pharmaceutically acceptable salts, respectively.

11. (Original) Pharmaceutical composition according to claim 9, containing pharmacological doses of R-4-trimethylammonio-3-(tetradecylcarbamoyl)-aminobutyrate or one of its pharmaceutically acceptable salts and subpharmaceutical doses of metformin or one of its pharmaceutically acceptable salts.

12. (Original) Pharmaceutical composition according to claim 9, containing subpharmacological doses of R-4-trimetyl-ammonio-3-(tetradecylcarbamoyl)-aminobutyrate or one of its pharmaceutically acceptable salts and pharmacological doses of metformin or one of its pharmacologically acceptable salts, respectively.

13. (Original) Pharmaceutical composition according to claim 9, containing pharmacological doses of R-4-trimetyl-ammonio-3-(tetradecylcarbamoyl)-aminobutyrate or one of its pharmaceutically acceptable salts and pharmacological doses of metformin or one of its pharmacologically acceptable salts, respectively.

14. (Previously Presented) Pharmaceutical composition according to claim 9, containing R-4-trimethylammonio-3-(tetradecyl-carbamoyl)-aminobutyrate or one of its pharmaceutically acceptable salts and metformin or one of its pharmaceutically acceptable salts in a single dosage form.

15. (Original) Pharmaceutical composition according to claim 14, where one dosage unit is suitable for the therapeutic coverage of the nocturnal fasting period.

16. (Previously Presented) Pharmaceutical composition according to claim 9, in which ST 1326 is present at a dose ranging from 10 mg to 1 g or an equivalent dose of one of its pharmaceutically acceptable salts, and metformin is present at a dose ranging from 50 mg to 2.5 g or an equivalent dose of one of its pharmaceutically equivalent salts.